ProKidney [PROK] vs Vertex [VRTX] Detailed Stock Comparison
ProKidney
NASDAQ
Loading...
Vertex
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: ProKidney wins in 6 metrics, Vertex wins in 11 metrics, with 0 ties. Vertex appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | ProKidney | Vertex | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -3.69 | 27.94 | ProKidney |
| Price-to-Book Ratio | 0.88 | 5.86 | ProKidney |
| Debt-to-Equity Ratio | 1.30 | 8.89 | ProKidney |
| PEG Ratio | 0.20 | -0.22 | Vertex |
| EV/EBITDA | -8.17 | 19.96 | ProKidney |
| Profit Margin (TTM) | 0.00% | 31.86% | Vertex |
| Operating Margin (TTM) | -17,967.87% | 38.93% | Vertex |
| EBITDA Margin (TTM) | N/A | 38.93% | N/A |
| Return on Equity | -40.52% | 22.77% | Vertex |
| Return on Assets (TTM) | -25.30% | 13.09% | Vertex |
| Free Cash Flow (TTM) | $-155.86M | $-978.00M | ProKidney |
| Dividend Yield | 305.81% | N/A | N/A |
| 1-Year Return | -1.26% | -18.80% | ProKidney |
| Price-to-Sales Ratio (TTM) | 3,206.54 | 8.82 | Vertex |
| Enterprise Value | $1.39B | $95.85B | Vertex |
| EV/Revenue Ratio | 2,638.57 | 8.39 | Vertex |
| Gross Profit Margin (TTM) | N/A | 86.25% | N/A |
| Revenue per Share (TTM) | $0 | $44 | Vertex |
| Earnings per Share (Diluted) | $-0.56 | $14.06 | Vertex |
| Beta (Stock Volatility) | 1.81 | 0.44 | Vertex |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
ProKidney vs Vertex Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| ProKidney | -8.27% | 4.02% | -27.64% | 187.65% | 48.41% | 34.68% |
| Vertex | 0.23% | 0.77% | -14.77% | -11.32% | -17.17% | -3.70% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| ProKidney | -1.26% | -68.53% | -76.52% | -76.52% | -76.52% | -76.52% |
| Vertex | -18.80% | 38.72% | 44.75% | 191.50% | 1,034.28% | 2,139.31% |
Performance & Financial Health Analysis: ProKidney vs Vertex
| Metric | PROK | VRTX |
|---|---|---|
| Market Information | ||
| Market Cap | $1.69B | $100.71B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 2,365,640 | 3,532,160 |
| 90 Day Avg. Volume | 15,069,110 | 1,933,493 |
| Last Close | $2.33 | $390.76 |
| 52 Week Range | $0.46 - $7.13 | $362.50 - $519.88 |
| % from 52W High | -67.32% | -24.84% |
| All-Time High | $14.19 (Mar 13, 2023) | $519.88 (Nov 04, 2024) |
| % from All-Time High | -83.58% | -24.84% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.04% | 0.12% |
| Quarterly Earnings Growth | N/A | 0.12% |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | 0.32% |
| Operating Margin (TTM) | -179.68% | 0.39% |
| Return on Equity (TTM) | -0.41% | 0.23% |
| Debt to Equity (MRQ) | 1.30 | 8.89 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $-7.51 | $67.02 |
| Cash per Share (MRQ) | $2.21 | $24.90 |
| Operating Cash Flow (TTM) | $-114,420,000 | $3.85B |
| Levered Free Cash Flow (TTM) | $-112,575,248 | $2.91B |
| Dividends | ||
| Last 12-Month Dividend Yield | 305.81% | N/A |
| Last 12-Month Dividend | $2.63 | N/A |
Valuation & Enterprise Metrics Analysis: ProKidney vs Vertex
| Metric | PROK | VRTX |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -3.69 | 27.94 |
| Forward P/E | -4.65 | 20.93 |
| PEG Ratio | 0.20 | -0.22 |
| Price to Sales (TTM) | 3,206.54 | 8.82 |
| Price to Book (MRQ) | 0.88 | 5.86 |
| Market Capitalization | ||
| Market Capitalization | $1.69B | $100.71B |
| Enterprise Value | $1.39B | $95.85B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 2,638.57 | 8.39 |
| Enterprise to EBITDA | -8.17 | 19.96 |
| Risk & Other Metrics | ||
| Beta | 1.81 | 0.44 |
| Book Value per Share (MRQ) | $-7.51 | $67.02 |
Financial Statements Comparison: ProKidney vs Vertex
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | PROK | VRTX |
|---|---|---|
| Revenue/Sales | $230,000 | $2.96B |
| Cost of Goods Sold | N/A | $407.50M |
| Gross Profit | N/A | $2.56B |
| Research & Development | $27.26M | $978.40M |
| Operating Income (EBIT) | $-41.39M | $1.15B |
| EBITDA | $-35.76M | $1.34B |
| Pre-Tax Income | $-37.36M | $1.28B |
| Income Tax | $591,000 | $250.10M |
| Net Income (Profit) | $-37.95M | $1.03B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | PROK | VRTX |
|---|---|---|
| Cash & Equivalents | $97.81M | $4.67B |
| Total Current Assets | $359.66M | $10.01B |
| Total Current Liabilities | $32.81M | $3.78B |
| Long-Term Debt | $2.51M | $1.65B |
| Total Shareholders Equity | $369.98M | $16.50B |
| Retained Earnings | $-1.22B | $10.25B |
| Property, Plant & Equipment | $3.07M | $2.63B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | PROK | VRTX |
|---|---|---|
| Operating Cash Flow | $-35.14M | $404.90M |
| Capital Expenditures | $-1.14M | $-40.70M |
| Free Cash Flow | $-30.73M | $778.20M |
| Debt Repayment | $-12,000 | $-1.30M |
| Common Stock Repurchase | N/A | $-696.60M |
Short Interest & Institutional Ownership Analysis
| Metric | PROK | VRTX |
|---|---|---|
| Shares Short | 7.57M | 4.36M |
| Short Ratio | 0.23 | 4.04 |
| Short % of Float | 0.08% | 0.02% |
| Average Daily Volume (10 Day) | 2,365,640 | 3,532,160 |
| Average Daily Volume (90 Day) | 15,069,110 | 1,933,493 |
| Shares Outstanding | 128.05M | 256.94M |
| Float Shares | 82.15M | 255.59M |
| % Held by Insiders | 0.29% | 0.00% |
| % Held by Institutions | 0.31% | 0.99% |
Dividend Analysis & Yield Comparison: ProKidney vs Vertex
| Metric | PROK | VRTX |
|---|---|---|
| Last 12-Month Dividend | $2.63 | N/A |
| Last 12-Month Dividend Yield | 305.81% | N/A |
| 3-Year Avg Annual Dividend | $3.15 | N/A |
| 3-Year Avg Dividend Yield | 36.48% | N/A |
| 3-Year Total Dividends | $9.44 | N/A |
| Ex-Dividend Date | Feb 14, 2025 | N/A |